⌘K
Fundamental leadership · SEC EDGAR · no analyst estimates · as of 2026-09-10
Which industries lead on earnings and sales, today. As of 2026-09-10, 4,465 companies clear the eligibility gates and 1,340 rank Leader or Strong on filed EPS and revenue growth. The strongest industry group is Precious Metals with 29 Leader or Strong names. 19.9% of eligible companies also sit in the top relative-strength quintile — fundamentals and price agreeing.
Theme
| Ticker | Company | Rank | Δ3wk | Verdict | EPS YoY | Sales YoY | Margin Δ | 6M RS | Filed |
|---|---|---|---|---|---|---|---|---|---|
| RANI | Rani Therapeutics Holdings, Inc. Class A Common StockObesity & Weight-Loss Therapeutics | 94 | ±0 | Leader | loss narrowed 78%↓ | — | — | 13 | 2026-08-13 |
| LLY | Eli Lilly & Co.Obesity & Weight-Loss TherapeuticsHuman Therapeutics | 93 | ±0 | Leader | +26% | +48% | +1051 bps | 66 | 2026-08-05 |
| ALT | Altimmune, Inc. Common StockObesity & Weight-Loss Therapeutics | 89 | -1 | Leader | loss narrowed 56%↑ | +420% | — | 32 | 2026-08-12 |
| AZN | AstraZeneca PLCObesity & Weight-Loss TherapeuticsHuman Therapeutics | 70 | ±0 | Strong | +27% | +12% | — | 28 | 2026-02-24 |
| AMGN | Amgen IncObesity & Weight-Loss TherapeuticsHuman Therapeutics | 63 | ±0 | Average | +65% | +10% | +653 bps | 51 | 2026-08-05 |
| BIOA | BioAge Labs, Inc. Common StockObesity & Weight-Loss Therapeutics | 61 | ±0 | Average | loss narrowed 3%↑ | +2%↓ | — | 8 | 2026-08-05 |
| ARWR | Arrowhead Research CorporationObesity & Weight-Loss TherapeuticsHuman Therapeutics | 58 | -1 | Average | loss widened 8% | +171% | -1498 bps | 88 | 2026-08-04 |
| NVO | Novo-Nordisk A/SObesity & Weight-Loss TherapeuticsHuman Therapeutics | 51 | -1 | Average | +2% | +6% | -289 bps | 67 | 2026-02-04 |
| REGN | Regeneron Pharmaceuticals IncObesity & Weight-Loss TherapeuticsHuman Therapeutics | 51 | ±0 | Average | -5% | +17% | -228 bps | 53 | 2026-07-30 |
| HIMS | Hims & Hers Health, Inc.Obesity & Weight-Loss Therapeutics | 43 | ±0 | Average | to loss↓ | +38% | -1223 bps | 58 | 2026-08-10 |
| SRRK | Scholar Rock Holding Corporation Common StockObesity & Weight-Loss Therapeutics | 28 | ±0 | Laggard | loss narrowed 14% | — | — | 82 | 2026-08-06 |
| MRK | Merck & Co., Inc.Obesity & Weight-Loss Therapeutics | 20 | ±0 | Laggard | to loss | +5% | -2119 bps | 79 | 2026-08-07 |
| CRBP | Corbus Pharmaceuticals Holdings, Inc.Obesity & Weight-Loss Therapeutics | 15 | ±0 | Laggard | loss widened 26% | -100% | — | 25 | 2026-08-06 |
| PFE | Pfizer Inc.Obesity & Weight-Loss TherapeuticsHuman Therapeutics | 14 | -1 | Laggard | to loss | +3% | -990 bps | 51 | 2026-08-04 |
| VKTX | Viking Therapeutics, IncObesity & Weight-Loss TherapeuticsHuman Therapeutics | 8 | ±0 | Laggard | loss widened 90%↑ | — | — | 36 | 2026-07-29 |
Every US common stock and ADR in the universe is ranked on fundamental growth from the numbers companies actually filed with the SEC — no analyst estimates, no forward projections. TickerStance reads EDGAR XBRL company facts directly.
To qualify, a company must have at least six quarters of EPS and revenue history available and the most-recent filing must be no older than 200 days. That gate keeps the rankings grounded in current operating conditions rather than stale data.
Two growth factors are computed: recent year-over-year growth (latest quarter vs the same quarter last year) blended with a three-year trend score. Both factors are percentile-ranked universe-wide so a rank of 90 means the company grows faster than 90% of its peers, regardless of absolute size. The two factor percentiles are then combined into a single 1-99 fundamentals rank.
Operating margin is tracked as context — a company whose margins are expanding while growing revenue is a stronger story than one shrinking margins to buy growth — but margin level is not a direct rank input. Industries, sectors, and themes inherit their rank from the median of their members, so a strong cluster is one where most constituent companies score well, not just a few outliers.
The RS overlap metric shows what share of a cluster's eligible companies sit in the top relative-strength quintile (6M RS rank ≥ 80). When a fundamentally strong group also carries broad price leadership, it has both the earnings story and the institutional sponsorship — the combination that historically precedes sustained outperformance.
Every US common stock and ADR with sufficient SEC filing history gets a 1-99 fundamentals rank: EPS and revenue growth factors are computed from filed XBRL data, percentile-ranked across the universe, and blended. Ranks of 90+ are Leaders, 70-89 Strong, 30-69 Average, below 30 Laggards. Industries, sectors, and themes are then ranked by their members' median rank.
SEC EDGAR XBRL company facts — the numbers companies actually filed. No analyst estimates, no forward guidance, no third-party data vendor.
Sign-aware: a narrowed loss counts as improvement, a widened loss as deterioration, a swing to profit as a turnaround. Conventional percent math misreads losses (a loss shrinking from -$0.12 to -$0.07 is improvement, not "down 42%"), so the table says "loss narrowed 42%" instead of printing a misleading percentage.
The change in a group's median fundamentals rank versus 15 and 30 trading days ago — the classic "improving group" read. Positive means the group is gaining rank. Dashes mean the history window isn't available yet.
Once per US trading day after the close. The as-of date in the header is the snapshot date.